EmpleoRelaciones con InversoresComunicados de PrensaCOVID-19
  1. Siemens Healthineers Colombia
  2. Diagnóstico de Laboratorio
  3. Assays by Diseases & Conditions
  4. Oncology
  5. Other Cancers

Other CancersColorectal, Ovarian, Pancreatic, Testicular, and Thyroid

Colorectal Cancer Testing

Carcinoembryonic Antigen (CEA) Assay
CEA belongs to a group of tumor markers referred to as oncofetal proteins. Increased serum CEA levels have been detected in persons with primary colorectal cancer1,2 and in patients with other malignancies including gastrointestinal tract, breast, lung, ovarian, prostatic, liver, and pancreatic cancers.1‑5
Siemens Healthineers offers the Carcinoembryonic Antigen (CEA) assay for in vitro diagnostic use in the quantitative measurement of carcinoembryonic antigen in human serum to aid in the management of cancer patients in whom changing concentrations of CEA are observed.

Siemens Healthineers CEA Assay Benefits

  • Improve patient management with information about patient prognosis, recurrence of tumors after surgical removal, and effectiveness of therapy.1‑6
  • Consolidate oncology testing on one trusted system for increased efficiency.

System availability: Atellica® IM Analyzer, ADVIA Centaur® CP/ XP/XPT Immunoassay Systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.

Ovarian Cancer Testing

CA 125II™ Assay
Siemens Healthineers CA 125II™ assay is for in vitro diagnostic use in the quantitative, serial determination of CA 125 in human serum and to aid in the management of patients with ovarian carcinoma. The test is also intended for use as an aid in the management of ovarian cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.7

Siemens Healthineers CA 125II Assay Benefits

  • Improve patient management with a useful tumor marker for evaluating therapy and monitoring disease status in patients under treatment for ovarian cancer.
  • Detect cancer recurrence early with a prognostic indicator of clinical outcome.
  • Consolidate oncology testing on one trusted system for increased efficiency.

System availability: Atellica® IM Analyzer, ADVIA Centaur® CP/ XP/XPT Immunoassay Systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.

Pancreatic Cancer Testing

CA 19-9 Assay
The Siemens Healthineers CA 19-9 assay is intended for use as an aid in monitoring patients previously treated for GI cancer. Serial testing for CA 19‑9 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of GI cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.8

Siemens Healthineers CA 19-9 Assay Benefits

  • Gain a test that is a more sensitive and specific marker of pancreatic cancer compared to other serologic markers.9
  • Achieve accurate results by utilizing the single most useful blood test in differentiating benign from malignant pancreatic disorders.10,11
  • Consolidate oncology testing on one trusted system for increased efficiency.

System availability: Atellica® IM Analyzer, ADVIA Centaur® CP/ XP/XPT Immunoassay Systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.

Testicular Cancer Testing

AFP Assay
The Siemens Healthineers AFP assay is for the quantitative determination of alpha-fetoprotein in human serum, as an aid in managing non-seminomatous testicular cancer when used in conjunction with physical examination, histology/pathology, and other clinical evaluation procedures.

Siemens Healthineers AFP Assay Benefits

  • Achieve good sensitivity with an established regimen for monitoring patients with non-seminomatous testicular cancer.12-15
  • Consolidate oncology testing on one trusted system for increased efficiency.

System availability: Atellica® IM Analyzer, ADVIA Centaur® CP/ XP/XPT Immunoassay Systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.

Thyroid Cancer Testing

Calcitonin Assay
The Siemens Healthineers Calcitonin (CALCT) Assay can be used as an aid in the diagnosis of medullary thyroid carcinoma (MTC), and to monitor the effectiveness of therapy and disease progression in patients with calcitonin-producing tumors in conjunction with other clinical and laboratory findings.

Siemens Healthineers Calcitonin Assay Benefits

  • Achieve accurate results with a calcitonin assay that has good precision across the range of the assay.
  • Delivers low-end sensitivity to monitor the effectiveness of therapy.
  • Eliminates high-dose hook effect up to 1,200,000 pg/mL (351,120 pmol/L), providing confidence in results.

System availability: Atellica® IM Analyzer, ADVIA Centaur® XP/XPT Immunoassay Systems and IMMULITE® 2000/2000 XPi Immunoassay System.
 

1
Statland BE, Winkel P. Neoplasia. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry: Theory, Analysis, and Correlation. 2nd ed. St. Louis, MO: CV Mosby; 1989:734–735.
2
Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prev. 1988;12(1–6):321–355.
3
Lahousen M, Stettner H, Pickel H, et al. The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer. Cancer. 1987;60(9):2228–2232.
4
Go VL, Zamcheck N. The role of tumor markers in the management of colorectal cancer. Cancer. 1982;50(11 suppl):2618–2623.
5
McNeely MD. Gastrointestinal function and digestive disease. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry: Theory, Analysis, and Correlation. 2nd ed. St. Louis, MO: CV Mosby;1989:411–412.
6
Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104(1):66–73.
7
10995283_EN Rev. 02, 2018-01.
8
10995285_EN Rev. 01, 2017-06.
9
Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110(9):704–709.
10
Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–355.
11
Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110(9):704–709.
12
Perlin E, Engeler JE, Edson M, et al. The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. Cancer. 1976;37:215–9.
13
Scardino PT, Cox HD, Waldmann TA, et al. The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol. 1977;118:994–9.
14
Javadpour N. The role of biologic tumor markers in testicular cancer. Cancer. 1980;45:1755–61.
15
Mason MD. Tumour markers. In:Horwich A, editor. Testicular Cancer Investigation and Management. Baltimore: Williams and Wilkins, 1991. 35–50.